Subcutaneous low doses of interleukin-2 and recombinant interferon alpha with carboplatin and vinblastine in patients with advanced melanoma (Journal article)

Bafaloukos, D./ Fountzilas, G./ Skarlos, D./ Pavlidis, N./ Bakoyiannis, C./ Karvounis, N./ Kosmidis, P.


Twenty-three patients with advanced melanoma were treated with a combination of subcutaneous recombinant human interleukin-2 (IL-2), and recombinant interferon alpha-2a (IFN-alpha) with chemotherapy consisting of four cycles of carboplatin (300 mg/m2, day 1) and vinblastine (6 mg/m2, day 1), every 28 days (CV-IL-IF). IL-2 was given at a dose of 4.5 x 10(6) U twice daily on days 3-6 and days 21-24 of each cycle; IFN-alpha dose was 4.5 x 10(6) U, starting on day 2, thrice weekly. Immunotherapy was intended to continue for 6 months. Of the 23 analyzed patients, 4 (17%) achieved an objective response, including 1 complete and 3 partial responses, in nonvisceral metastatic disease. The median time to progression was 5 months and the median survival from onset of the treatment 6 months (range 1-14 months). Four patients discontinued the treatment, due to nonhaematologic toxicity; 3 for severe weakness and the 4th patient for long-lasting CNS side-effects. Other grade 3-4 toxicities included weight loss (22%), nausea and vomiting (17%) and alopecia (13%). The haematologic toxicity was acceptable. No toxic death was noted. It is concluded that the CV-IL-IF regimen has limited activity and moderate toxicity.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adult,Aged,Antineoplastic Agents, Phytogenic/administration & dosage,Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use,Carboplatin/administration & dosage,Chemotherapy, Adjuvant,Female,Humans,Injections, Subcutaneous,Interferon-alpha/administration & dosage,Interleukin-2/administration & dosage,Male,Melanoma/*drug therapy/secondary,Middle Aged,Prospective Studies,Skin Neoplasms/*drug therapy/pathology,Survival Analysis,Treatment Outcome,Vinblastine/administration & dosage
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/18033
ISSN: 0030-2414
Link: http://www.ncbi.nlm.nih.gov/pubmed/9428375
http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000011834
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/18033
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.